



LAW OFFICES OF
SYNNESTVEDT & LECHNER LLP
2600 ARAMARK TOWER
1101 MARKET STREET
PHILADELPHIA, PA 19107-2950
TELEPHONE (215) 923-4466
FACSIMILE (215) 923-2189
E-MAIL synnlech@sunnlech.com
www.sunnlech.com

RECEIVED
MAY 20 2003
TECH CENTER 1600/2900

18/Prior Art

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re/ Application of T.A. Jeary, et al
Application No. 09/744,169
Filed April 19, 2001

Art Unit 1614
Examiner S. Tran

Multiparticulate Controlled Selective Serotonin Reuptake Inhibitor
Formulations.

(Attorney Docket No. P24,622 USA)

CERTIFICATE OF EXPRESS MAILING

I hereby certify that this correspondence, along with any papers indicated as being enclosed, are being deposited as Express Mail, (label EV 262354318 US), postage prepaid, in an envelope addressed to: Box Patent Application, The Commissioner for Patents, May 15, 2003.

Christopher Ricco

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Information Disclosure Statement Pursuant to 37 CFR §§ 1.56 and 1.97(b)(3)

Sir:

In accordance with applicants' duty of disclosure under 37 C.F.R. § 1.56 and the provisions of 37 C.F.R. §§ 1.97 and 1.98, it is respectfully requested that the references listed on the enclosed Form PTO-1449 in accordance with the provisions

Application No. 09/744,169
Art Unit 1614

May 15, 2003
S&L File No. P 24,622 USA
Page 2

of 37 C.F.R. § 1.98 be considered and made of record with respect to the above-referenced U.S. Patent Application. With the exception of U.S. Patent No. 4,085,225 which was cited in the specification, the references listed were cited on the International Search Report for the corresponding Patent Cooperation Treaty International Application No. PCT/IE00/00060.

Under Section 609 of the Manual of Patent Examining Procedure (M.P.E.P), the Examiner should consider the references cited in the International Search Report and indicate by a statement in the first Office Action that the references have been considered.

Applicants submit respectfully that none of the disclosed documents anticipate the invention and there is no reasonable combination of the disclosed documents that renders the invention obvious.

Submission of the present Information Disclosure Statement should not be construed as a representation that a search has been made, or as an admission that the cited references are legally available prior art or that the same are material to patentability.


The Examiner is requested respectfully to initial, date and return the enclosed copy of PTO Form 1449 upon consideration of the cited references. Copies of the references have already been provided to the Examiner by a Communication filed on January 16, 2003. If copies of the references were not received, the Examiner is invited to contact the undersigned so that duplicate copies can be promptly forwarded.

Application No.09/744,169
Art Unit 1755

May 15, 2003
S&L File P24,622 USA
Page 3

This Information Disclosure Statement is filed under 37 C.F.R. § 1.97(b) before the mailing of a first Office Action on the merits. Accordingly, no fees are believed due at this time. If any fees are deemed due, the Commissioner is authorized to charge Deposit Account No. 19-5425. A duplicate copy of this sheet is enclosed to facilitate the process.

Respectfully submitted
Synnestvedt & Lechner LLP



Jane E. Alexander
Reg. No. 36,014

Synnestvedt & Lechner LLP
2600 Aramark Tower
1101 Market Street
Philadelphia, PA 19107-2950
Telephone (215)-923-4466
Facsimile (215)-923-2189
E-mail - jalexander@synnlech.com